[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ciprofol\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ciprofol":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,72,96,126,152],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100054244","phase-4-the-ed95-of-ciprofol-for-laryngeal-mask-airway-insertion-with-fentanyl-in-children-a-biased-coin-dose-finding-trial-100054244",false,"NCT07697404","The ED95 of Ciprofol for Laryngeal Mask Airway Insertion With Fentanyl in Children: A Biased-Coin Dose-Finding Trial","Inclusion Criteria:\n\n* American Society of Anesthesiologists (ASA) physical status I or II\n* Aged 1 to 12 years\n* Scheduled for elective surgery requiring general anesthesia with laryngeal mask airway (LMA) insertion (e.g., ophthalmic surgery, skin lesion excision, minor abdominal or urological procedures, with expected surgical duration ≤ 2 hours)\n* Written informed consent obtained from parents or legal guardians\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to ciprofol, fentanyl, or any study-related drugs\n* Intellectual disability, cognitive-affective disorders, psychiatric or neurological diseases\n* Inability to cooperate with peripheral intravenous cannulation\n* History of reactive airway disease or suspected difficult airway\n* Body mass index (BMI) ≥ 30 kg\u002Fm² or ≤ 15 kg\u002Fm²\n* History of sedative medication use\n* Inability to understand the study protocol or participation in another clinical trial within the past 30 days","ALL","1 Year","12 Years",{"count":19,"type":20},180,"ESTIMATED","INTERVENTIONAL",[23],"PHASE4","Ciprofol is a novel intravenous anesthetic with a pharmacological profile similar to propofol but with a lower incidence of injection pain, hypotension, and respiratory depression. For pediatric day-case surgeries, laryngeal mask airway (LMA) insertion without neuromuscular blockers is increasingly preferred. While opioids are often combined with hypnotics to optimize insertion conditions, the optimal bolus dose of ciprofol when co-administered with a standard dose of fentanyl for LMA insertion in children remains unknown. This study aims to determine the 95% effective dose (ED95) of a single intravenous bolus of ciprofol, combined with a fixed dose of fentanyl (1 μg\u002Fkg), for successful LMA insertion in children aged 1-12 years during general anesthesia induction.",[26,27,28,29],"Pediatric","Anesthesia Induction","Ciprofol","Laryngeal Mask Airway","RECRUITING","2026-07-10",{"date":33,"type":34},"2026-07-13","ACTUAL",{"date":36,"type":34},"2026-06-15",{"date":38,"type":20},"2028-12-01",{"name":40,"class":41},"Huazhong University of Science and Technology","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":15,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":21,"phases":55,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100621896","efficacy-and-safety-of-anricofen-combined-with-ciprofol-for-deep-sedation-in-elderly-patients-undergoing-ercp-100621896","NCT07376577","Efficacy and Safety of Anricofen Combined With Ciprofol for Deep Sedation in Elderly Patients Undergoing ERCP","A Randomized Controlled Trial on the Efficacy and Safety of Anricofen Combined With Ciprofol for Deep Sedation in Elderly Patients Undergoing Endoscopic Retrograde Cholangiopancreatography","Anricofen Cipr","Inclusion Criteria:\n\n\\-\n\nInclusion Criteria:\n\n1. Age 60-90 years.\n2. American Society of Anesthesiologists (ASA) physical status II or III.\n3. Scheduled for elective endoscopic retrograde cholangiopancreatography (ERCP).\n4. Body mass index (BMI) between 18 and 30 kg\u002Fm².\n5. Willing and able to provide written informed consent.\n\nExclusion Criteria:\n\n1. Severe neurological disorders (acute stroke, uncontrolled seizures, epilepsy).\n2. Psychiatric disorders or cognitive impairment (Mini-Mental State Examination score \\\u003C24).\n3. Uncontrolled hypertension (preoperative blood pressure ≥180\u002F110 mmHg) or hypotension (\\\u003C90\u002F60 mmHg).\n4. Severe cardiac disease: sinus bradycardia, sick sinus syndrome, unstable angina, or myocardial infarction within the past 3 months.\n5. Severe hepatic or renal dysfunction.\n6. Difficult airway or severe respiratory disease.\n7. Achalasia.\n8. Known allergy to anricofen, sufentanil, ciprofol, or other study medications.\n9. Use of opioid analgesics or sedatives within 7 days prior to surgery.\n10. Preoperative pulse oxygen saturation (SpO₂) \\\u003C90% on room air.\n11. Pregnancy or lactation.\n12. Participation in any other drug clinical trial within the past 3 months.\n13. Refusal to participate in the study.\n\nExclusion Criteria:\n\n\\-","60 Years","90 Years",{"count":54,"type":20},141,[56],"NA","Background: Endoscopic retrograde cholangiopancreatography (ERCP) is a key technique for treating pancreatobiliary diseases in the elderly. However, traditional sedative and analgesic regimens (e.g., sufentanil combined with propofol) are associated with a high incidence of respiratory depression, postoperative nausea and vomiting (PONV), and delayed recovery in elderly patients. Anricofen is a novel peripherally selective κ-opioid receptor agonist that provides analgesia with minimal central respiratory depression. Ciprofol is a new sedative agent characterized by rapid onset and quick recovery. The combination of these two drugs may offer a safer sedation and analgesia regimen for elderly patients undergoing ERCP.\n\nObjective: To evaluate the efficacy and safety of anricofen combined with ciprofol for deep sedation in elderly patients undergoing ERCP, compared with the traditional regimen (sufentanil combined with ciprofol).\n\nMethods: This is a single-center, randomized, double-blind, controlled trial. A total of 141 elderly patients aged 60-90 years with ASA physical status II-III scheduled for elective ERCP will be enrolled and randomly assigned in a 1:1:1 ratio to three groups: Anricofen 0.3 μg\u002Fkg + Ciprofol 1.0 mg\u002Fkg, Anricofen 0.5 μg\u002Fkg + Ciprofol 1.0 mg\u002Fkg, or Sufentanil 0.1 μg\u002Fkg + Ciprofol 1.0 mg\u002Fkg. The primary efficacy endpoint is the intraoperative pain control success rate (proportion of time with Behavioral Pain Scale \\[BPS\\] score ≤3 ≥90%). The primary safety endpoint is the incidence of respiratory depression (respiratory rate \\\u003C10 breaths\u002Fmin or SpO₂ \\\u003C90% requiring intervention). Secondary outcomes include sedation depth, body movement episodes, recovery time, PONV incidence, and others.\n\nSignificance: This study aims to provide a sedation and analgesia regimen with lower risk of respiratory depression and faster recovery for elderly patients undergoing ERCP.",[59,60,61,28],"Anesthesia","Sedation","ERCP","NOT_YET_RECRUITING","2026-01-26",{"date":65,"type":34},"2026-01-29",{"date":67,"type":20},"2026-01-01",{"date":69,"type":20},"2028-05-01",{"name":71,"class":41},"The First Affiliated Hospital of Xinxiang Medical College",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":15,"minAge":79,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":21,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":42},"100589299","phase-4-effect-of-ciprofol-on-intraoperative-hypotension-in-elderly-patients-receiving-renin-angiotensin-system-inhibitors-100589299","NCT06952608","Effect of Ciprofol on Intraoperative Hypotension in Elderly Patients Receiving Renin-angiotensin System Inhibitors","The Effect of Ciprofol on Intraoperative Hypotension in Elderly Patients Receiving Renin-angiotensin System Inhibitors: a Prospective, Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients undergoing elective abdominal surgery under general anesthesia\n2. Duration of surgery exceeding 2 hours\n3. Patients receiving long-term renin-angiotensin system inhibitor therapy (\\>3 months prior to surgery)\n4. Age ≥ 65 years\n5. ASA classification II-III\n6. Informed consent was obtained from patients or their guardians\n\nExclusion Criteria:\n\n1. History of allergy to opioids, propofol, or ciprofol components.\n2. Anticipated difficult airway (limited mouth opening, restricted neck movement, or modified Mallampati grade III-IV) or difficult mask ventilation.\n\n   Body mass index ≤18 or ≥35 kg\u002Fm².\n3. Severe hepatic dysfunction (total bilirubin ≥3.0 mg\u002FdL or AST\u002FALT ≥2 times the upper limit of normal).\n4. Severe renal impairment (creatinine clearance ≤30 mL\u002Fmin).\n5. Cardiac diseases (AV block higher than first-degree, heart rate \\\u003C50 bpm, severe arrhythmias, severe valvular heart disease, heart failure, or unstable angina on the day of surgery).\n6. Preoperative cognitive impairment, cerebrovascular disease, or history of psychiatric illness.\n7. Abnormal thyroid-stimulating hormone levels or history of thyroid replacement therapy.\n8. Unstable asthma or history of asthma.\n9. Alcohol abuse, drug abuse, chronic opioid dependence, or analgesic use exceeding 3 months.\n10. Lactating or pregnant women.","65 Years",{"count":81,"type":20},140,[23],"The prevention of intraoperative hypotension could reduce postoperative organ injury and mortality, particularly in elderly patients receiving long-term renin-angiotensin system inhibitors. Previous meta-analyses suggest that ciprofol, a novel intravenous anesthetic agent, may provide improved hemodynamic stability compared to propofol; however, its precise effects on perioperative hemodynamics remain unclear. The study will assess whether ciprofol improves perioperative hemodynamic stability in elderly patients receiving renin-angiotensin system inhibitors.",[85,28,86],"Intraoperative Hypotension","Renin-angiotensin System Inhibitors","2025-12-22",{"date":89,"type":34},"2025-12-30",{"date":91,"type":34},"2025-04-10",{"date":93,"type":20},"2026-04-10",{"name":95,"class":41},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":105,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":21,"phases":110,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":125},"100603102","reinforcement-learned-automated-anesthesia-systems-during-painless-abortion-100603102","NCT07132151","Reinforcement Learned Automated Anesthesia Systems During Painless Abortion","Automated Anesthesia Systems for Painless Abortion (AAS-PA): a Multi-center, Randomized Controlled Trial","AAS-PA","Inclusion Criteria:\n\n* Age between 18-45 years\n* ASA status Ⅰ to Ⅱ\n* Diagnosed with early intrauterine pregnancy\n* Body mass index (BMI) between 18 to 28 kg\u002Fm2\n\nExclusion Criteria:\n\n* History of cardiac, hepatic, renal, or metabolic disorders (e.g., diabetes, hypertension, sleep apnea)\n* Known allergy to opioids or ciprofloxacin components\n* Cachexia\n* History of substance or alcohol abuse\n* ASA class III or higher\n* Participation in any other drug clinical trial within the past 3 months\n* Long-term use of sedative or analgesic medications\n* History of neurological disorders and convulsions",true,"FEMALE","18 Years","45 Years",{"count":109,"type":20},167,[56],"This study compares the automated anesthesia systems for painless abortion (AAS-PA) with traditional anesthesia in painless abortions. It assesses intraoperative indicators (hypoxemia, injection pain, hypotension, hemodynamics, respiratory depression) and postoperative outcomes (nausea, dizziness, recovery time, satisfaction). The AAS-PA group uses AI-adjusted intravenous ciprofol based on real-time vital signs and sedation depth; the traditional group relies on manual anesthesia. The goal is to verify if AAS-PA safely manages sedation, meets painless standards, reduces adverse events, and improves experience, aiding optimized automated protocols.",[113,114,28],"Painless Abortion","Artificial Intelligence (AI)","2025-08-18",{"date":117,"type":34},"2025-08-20",{"date":119,"type":20},"2025-09-08",{"date":121,"type":20},"2027-11-08",{"name":123,"class":124},"Boston Intelligent Medical Research Center, Shenzhen United Scheme Technology Co., Ltd.","INDUSTRY",8,{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":104,"sex":15,"minAge":79,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":136,"briefSummary":137,"conditions":138,"keywords":139,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":4},"100599206","ciprofols-influence-on-lvot-vti-in-elderly-painless-colonoscopy-patients-100599206","NCT07081477","Ciprofol's Influence on LVOT VTI in Elderly Painless Colonoscopy Patients","Effect of Ciprofol on Left Ventricular Outflow Tract Velocity-Time Integral in Elderly Patients Undergoing Painless Colonoscopy","Inclusion Criteria:\n\n1. ASA classification I-III;\n2. Age ≥65 years and ≤80 years;\n3. BMI between 18-30 kg\u002Fm2 (including the threshold);\n4. Patients undergoing painless colonoscopy on an elective basis;\n5. Subjects voluntarily participated in this study and signed an informed consent form.\n\nExclusion Criteria:\n\n1. Those with respiratory depression or high risk of respiratory depression (e.g., sleep apnea syndrome, bronchial asthma, etc.);\n2. Suffering from major diseases such as severe hepatic and renal insufficiency, neurological and psychiatric systems;\n3. Suffering from severe arrhythmias such as severe aortic regurgitation, atrial fibrillation, tachycardia (heart rate \\> 120 beats\u002Fminute), atrioventricular block of degree II and above, myocardial infarction or unstable angina within 6 months before the examination, and NYHA classification grade II and above;\n4. Allergy to or abuse of any medication used in the study;\n5. Participation in another clinical trial within the last 3 months.","80 Years",{"count":135,"type":20},120,[56],"1. Objective:\n\n   Primary: Compare the effect of Ciprofol vs Propofol on LVOT VTI at 2 minutes post-injection (T1) in elderly patients (≥65 years).\n\n   Secondary: Assess hypotension incidence, injection pain, nausea\u002Fvomiting, hypoxia (SpO₂≤90%), bradycardia (HR\\\u003C50 bpm), sedation success rate, induction\u002Frecovery times, procedure duration, drug doses, and patient satisfaction.\n2. Design:\n\n   Single-center, randomized, double-blind, controlled trial. Group C (Ciprofol):0.2-0.5 mg\u002Fkg IV induction (\\>30s injection). Group P (Propofol)::1-2 mg\u002Fkg IV induction (\\>30s injection). Rescue doses allowed (C: 0.1 mg\u002Fkg; P: 0.5 mg\u002Fkg; max 5 doses\u002F15 min).\n3. Participants:\n\n   N = 120 elderly patients (65-80 years, ASA I-III, BMI 18-30 kg\u002Fm²) scheduled for elective painless colonoscopy.\n\n   Exclusion: Significant cardiorespiratory, hepatic, renal, or neurological disorders; recent MI\u002Funstable angina (≤6 months); NYHA ≥II; drug allergies; recent trial participation.\n4. Key Assessments:\n\n   Primary Endpoint: LVOT VTI (via transthoracic echocardiography, TTE) at T1.\n\n   Secondary Endpoints:\n\n   Adverse events (hypotension, pain, nausea\u002Fvomiting, hypoxia, bradycardia, body movement, awareness).\n\n   Sedation success rate, induction\u002Frecovery times (MOAA\u002FS scale), procedure time. Drug doses (induction, total, vasoactive agents). Patient satisfaction (5-point scale). LVEF and IVC Collapse Index (TTE at T0, T1, T2). Safety: Vital signs (HR, BP, SpO₂).\n5. Statistical Analysis:\n\nSPSS 26.0; α=0.05. Methods: t-test, RM-ANOVA, Mann-Whitney U, Chi-square\u002FFisher's exact, rank-sum tests.\n\nThis study aims to determine whether Ciprofol provides superior hemodynamic stability (as measured by LVOT VTI) and fewer adverse effects compared to Propofol for sedation in elderly patients undergoing painless colonoscopy.",[28],[140,141,142],"Painless colonoscopy","Propofol","Left Ventricular Outflow Tract Velocity Time Integral","2025-07-15",{"date":145,"type":34},"2025-07-23",{"date":147,"type":20},"2025-08-25",{"date":149,"type":20},"2027-06-30",{"name":151,"class":41},"The First People's Hospital of Lianyungang",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":104,"sex":15,"minAge":158,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":42},"100583949","comparison-of-ciprofol-and-propofol-under-ioc1-and-ioc2-monitoring-for-adenotonsillectomy-100583949","NCT06882980","Comparison of Ciprofol and Propofol Under IoC1 and IoC2 Monitoring for Adenotonsillectomy","Inclusion Criteria:\n\n* ASA I\u002FII, age 3-11 years, weight 13-50 kg.\n\nEndoscopic T\\&A or adenoidectomy.\n\nExclusion Criteria:\n\n* Recent upper respiratory infection.\n\nDifficult airway, organ dysfunction, developmental\u002Fpsychiatric disorders.\n\nDrug allergies.","3 Years","11 Years",{"count":161,"type":20},236,[56],"The goal of this clinical trial is to compare the Ciprofol and Propofol Under IoC1 and IoC2 Monitoring for Adenotonsillectomy Participants will be randomly allocated to two groups: Ciprofol group (Group C) and Propofol group (Group P). For those in Group C: they will be given ciprofol during anesthesia induction and maintenance .For those in Group P: they will be pgiven ciprofol during anesthesia induction and maintenanc This study evaluates ciprofol versus propofol under IoC1\u002FIoC2 guidance in pediatric T\\&A, providing evidence for ciprofol's efficacy and safety in pediatric anesthesia.",[165,141,28],"Adenotonsillectomy","2025-06-11",{"date":168,"type":34},"2025-06-12",{"date":170,"type":34},"2025-02-22",{"date":172,"type":20},"2025-11-22",{"name":174,"class":41},"Maternal and Child Health Hospital of Hubei Province"]